CinFina’s ‘next-generation’ mechanisms shine at ObesityWeek

4 November 2024

CinFina Pharma, a CinRx portfolio developing a portfolio of treatment options for obesity, has presented positive top-line interim results from its Phase I single ascending dose (SAD) study of CIN-110 and final data from its multiple ascending dose (MAD) study of CIN-109.

Both programs demonstrated tolerability and meaningful weight loss, according to the data shared at ObesityWeek 2024.

CIN-110 is a novel, long-acting PYY3-36 analog designed to significantly reduce gastrointestinal (GI) side effects following subcutaneous (SC) administration. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical